Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease

• Renuka Pudi Limgala ,

  * E-mail: rlimgala@ldrtc.org

  Affiliations Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States of America, Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America

  http://orcid.org/0000-0001-6957-6284

  ⨯
• Chidima Ioanou,

  Affiliation Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States of America

  ⨯
• Matthew Plassmeyer,

  Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America

  ⨯
• Mark Ryherd,

  Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America

  ⨯
• Lina Kozhaya,

  Affiliation Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America

  ⨯
• Lauren Austin,

  Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America

  ⨯
• Cem Abidoglu,

  Affiliation Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America

  ⨯
• Derya Unutmaz,

  Affiliation Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, United States of America

  ⨯
• Oral Alpan,

  Affiliation Amerimmune, O and O Alpan, LLC, Fairfax, Virginia, United States of America

  ⨯
• Ozlem Goker-Alpan

  Affiliation Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, Virginia, United States of America

  ⨯